Efficacy and Safety of Pomegranate Medicinal Products for Cancer

Table 1

Quality criteria considered in the 4 trials investigating pomegranate products.

	Clin cancer Res; 2006; 12: 4018–26; Pantuck et al. [36]	Prostate cancer prostatic Dis; 2013; 16: 50–5; Paller et al. [37]	J cancer; 2013; 4: 597–605; Stenner-Liewen et al. [40]	Cancer prev Res (Phila); 2013; 6: 1120–7; Freedland et al. [38]
	= 46	= 92	= 97	= 69
SM	Juice POM wonderful	extract POMx	Pomegranate blend	Extract POMx
Dose	240 mL/day	1000 mg versus 2000 mg/day	500 mL/day	mg/day
pa	570 mg/day	Not stated	700 mg/day^*	1200 mg/day
cai	Not stated^*	400 mg versus 800 mg/day	40 mg/day	Not stated^*
	Open, uncontrolled	Low dose (45), high dose (47)	Placebo (48), control (49)	Placebo (36), control (33)
D	13 months	Up to 18 months	4 weeks	4 weeks
R	Lengthening of PSA doubling time	No difference between groups lengthening of PSA doubling time	No difference between groups	No difference between groups
A	Prostate cancer	Prostate cancer	Prostate cancer	Prostate cancer requiring Radical prostatectomy
B	Not applicable	Not stated	Yes	Yes
C	Not applicable	Not stated	Yes	Yes
E	Not applicable	Not stated	Yes	Yes
F	Not applicable	Yes	Yes	Yes
G	Not applicable	Yes	Yes	Yes
H	Yes	Yes	Yes	Yes
I	Yes	Yes	Yes	Not stated
J	Yes	Yes	Yes	Yes (none)
K	Yes	Yes	Yes	Yes
L	No	Yes	No	No
N	No	No	No	No
O	Yes	Yes	No	No
TS	6	9	10	9
	^*according to Paller the same as in extract POMx	^*from other source see Hong et al., 2008 [14]	^*see Chrubasik-Hausmann et al. 2014a [41]	^*no details given on request

SM study medication, pa photometrically assessed, cai coactive ingredients/day (HPLC) D duration of treatment, R result.
Quality criteria A: eligibility criteria specified, B: randomization appropriate, C: treatment allocation concealed, E: similarity at baseline, F: outcome measures and control interventions explicitly described, G: cointerventions comparable, H: outcome measures relevant, I: adverse events and J drop-outs fully described, K: sample size based on a priori power calculation, L: intention-to-treat analysis, N: point estimates and measures of variability presented for the primary outcome measure, and O: appropriate timing giving a total score (TS) of 13.